Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BAY 43-9006: preclinical data.

Scott Wilhelm1, Du-Shieng Chien

  • 1Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA. scott.wilhelm.b@bayer.com

Current Pharmaceutical Design
|October 9, 2002
PubMed
Summary

A novel small molecule inhibitor, BAY 43-9006, effectively blocks the Raf/MEK/ERK pathway. This bis-aryl urea compound demonstrates potent Raf-1 kinase inhibition and anti-tumor efficacy in preclinical models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same author

Parathyroid Carcinoma Mimicking Thyroid Hyalinizing Trabecular Tumor: A Case Report and Review of Atypical Presentations of Parathyroid Carcinoma.

International journal of surgical pathology·2026
Same author

Commentary: CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.

Pathology oncology research : POR·2026
Same author

CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.

Pathology oncology research : POR·2023
Same author

American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.

JAMA surgery·2022
Same author

Primary hyperparathyroidism after radioactive iodine therapy: Is it a distinct clinical entity?

American journal of surgery·2022

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Oncology

Background:

  • The Raf/MEK/ERK signaling pathway is frequently dysregulated in various cancers.
  • Targeting Raf-1 kinase offers a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To report the development and characterization of a novel small molecule inhibitor of Raf-1 kinase.
  • To evaluate the anti-tumor efficacy of BAY 43-9006 in preclinical cancer models.

Main Methods:

  • Medicinal chemistry optimization led to the identification of BAY 43-9006, a bis-aryl urea.
  • In vitro assays determined Raf-1 inhibition (IC(50) = 12 nM) and kinase selectivity.
  • In vivo studies assessed pathway blockade and anti-tumor activity in human xenograft models.

Main Results:

  • BAY 43-9006 exhibited potent and selective inhibition of Raf-1 kinase.
  • The compound effectively blocked the Raf/MEK/ERK signaling pathway in tumor cells.
  • BAY 43-9006 demonstrated significant anti-tumor efficacy in human xenograft models.

Conclusions:

  • BAY 43-9006 is a promising novel Raf-1 kinase inhibitor with demonstrated anti-tumor activity.
  • This compound represents a potential new therapeutic agent for cancers driven by the Raf/MEK/ERK pathway.

Related Experiment Videos